Daveen Chopra - 14 Jun 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Surgical Structural Heart
Signature: Linda J. Park, Attorney-in-Fact
Issuer symbol: EW
Transactions as of: 14 Jun 2021
Net transactions value: -$1,312,349
Form type: 4
Filing time: 14 Jun 2021, 21:21:24 UTC
Previous filing: 19 May 2021
Next filing: 05 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$1,086,641	+24,000	+152%	$45.28	39,827	14 Jun 2021	Direct	F1
transaction	EW	Common Stock	Sale	$2,398,990	-24,000	-60%	$99.96	15,827	14 Jun 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-24,000	-50%	$0.000000	24,435	14 Jun 2021	Common Stock	24,000	$45.28	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2021.
F2	This transaction was executed in multiple trades at prices ranging from $99.58 to $100.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.